Statistics from Altmetric.com
- Atrial fibrillation
- anti-arrhythmic drugs
- stable angina
- coronary artery disease (CAD)
- paediatric cardiology
- heart transplant
- congenital heart disease
To the Editor The important report by Alboni et al1 not only documents risks associated with the use of propafenone during ‘pill-in-the-pocket’ (PIP) therapy for paroxysmal atrial fibrillation (PAF) but also hints at techniques by which its use may be made safer. The primary metabolism of propafenone occurs through hepatic CYP4502D6 isoenzyme activity, resulting in differences between the safety of propafenone administered intravenously and orally.
CYP2D6 activity may also be strongly inhibited by other commonly prescribed medications, including quinidine, amiodarone, cimetidine, erythromycin and most selective serotonin re-uptake inhibitor antidepressants, …
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.